HRMY — Harmony Biosciences Holdings, Inc.
HRMY dilution and offerings
- Float: 45.7M shares
🔔 Alert me if HRMY files an offering or S-3
$37.91-2.19%
Last close: · regular session
Last 60 sessions
Float: 45.7M shares. Latest SEC filing: 8-K/A on Oct 30, 2026. HRMY closed at $37.91 (-2.19%) on Nov 2, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for HRMY in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 268
- Website: https://www.harmonybiosciences.com
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Latest SEC filings for HRMY
Latest HRMY news
- Harmony Biosciences Holdings, Inc. Q3 2026 Earnings Preview Read article
- Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth Read article
- Harmony Biosciences drops amid court hearing on Wakix patent Read article
- HRMY or ARGX: Which Is the Better Value Stock Right Now? Read article
- Why Harmony Biosciences Stock Got Mashed on Monday Read article
- Harmony Biosciences appoints Peter Anastasiou as CEO Read article
- Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth Read article
- Harmony Bio CEO Plans His Exit, And Shares Take An Unharmonious Hit Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.